Neyssa Marina

Publications

• A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Felgenhauer JL, Nieder ML, Krailo MD, Bernstein ML, Henry DW, Malkin D, Baruchel S, Chuba PJ, Sailer SL, Brown K, Ranganathan S, Marina N. Pediatr Blood Cancer. 2013; 60 (3): 409-14
• Changes in Health Status Among Aging Survivors of Pediatric Upper and Lower Extremity Sarcoma: A Report From the Childhood Cancer Survivor Study. Marina N, Hudson MM, Jones KE, Mulrooney DA, Avedian R, Donaldson SS, Popat R, West DW, Fisher P, Leisenring W, Stovall M, Robison LL, Ness KK. Arch Phys Med Rehabil. 2013
• Children's Oncology Group's 2013 blueprint for research: Bone tumors. Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N. Pediatr Blood Cancer. 2013; 60 (6): 1009-15
• Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, Lor Randall R, Lee S, Kim G, Bernstein M, Gorlick R, Krailo M, Marina N. Eur J Cancer. 2013
• Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy. Baggott C, Cooper BA, Marina N, Matthay KK, Miaskowski C. Cancer Nurs. 2012 Jan-Feb; 35 (1): 19-28
• Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N. Cancer. 2012; 118 (18): 4597-605
• Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N. J Clin Oncol. 2012; 30 (20): 2545-51
• Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Sharib JM, Cyrus J, Horvai A, Gray Hazard FK, Neuhaus J, Matthay KK, Goldsby R, Marina N, DuBois SG. Pediatr Blood Cancer. 2012; 59 (4): 611-6
• An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy. Baggott CR, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper B, Miaskowski C. Support Care Cancer. 2011; 19 (3): 353-61
• Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group. Hingorani P, Seidel K, Krailo M, Mascarenhas L, Meyers P, Marina N, Conrad EU, Hawkins DS. Pediatr Blood Cancer. 2011; 57 (6): 939-42
• High-intensity focused ultrasound (HIFU) is not indicated for treatment of primary bone sarcomas. Bielack SS, Marina N, Bernstein M. Cancer. 2011; 117 (12): 2822; author reply 2822-3
• Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N. Cancer. 2011; 117 (3): 625-34
• Changes in children's reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy. Baggott C, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper BA, Miaskowski C. J Pediatr Oncol Nurs. 2010 Nov-Dec; 27 (6): 307-15
• Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. DuBois SG, Marina N, Glade-Bender J. Cancer. 2010; 116 (3): 749-57
• Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER. J Clin Oncol. 2010; 28 (12): 1989-94
• Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES. Clin Cancer Res. 2010; 16 (15): 4024-30
• Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study. Lansdale M, Castellino S, Marina N, Goodman P, Hudson MM, Mertens AC, Smith SM, Leisenring W, Robison LL, Oeffinger KC. Cancer. 2010; 116 (4): 974-82
• The role of interferons in the treatment of osteosarcoma. Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M. Pediatr Blood Cancer. 2010; 54 (3): 350-4
• Multiple symptoms in pediatric oncology patients: a systematic review. Baggott C, Dodd M, Kennedy C, Marina N, Miaskowski C. J Pediatr Oncol Nurs. 2009 Nov-Dec; 26 (6): 325-39
• Anti-insulin growth factor receptor therapy in Ewing sarcoma. Isakoff MS, Marina N. F1000 Med Rep. 2009 1
• Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A, Miser J, Meyer J, Arndt CA, Sailer S, Marcus K, Perlman E, Dickman P, Grier HE. J Clin Oncol. 2009; 27 (15): 2536-41
• Immune approaches to treating osteosarcoma. Marina N, Gorlick R. Cancer Biol Ther. 2009; 8 (10): 981-3
• International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, Butterfass-Bahloul T, Calaminus G, Bernstein M. Cancer Treat Res. 2009: 152 339-53
• Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE, Stegmaier K. Pediatr Blood Cancer. 2009; 52 (3): 324-7
• Physical performance limitations in the Childhood Cancer Survivor Study cohort. Ness KK, Hudson MM, Ginsberg JP, Nagarajan R, Kaste SC, Marina N, Whitton J, Robison LL, Gurney JG. J Clin Oncol. 2009; 27 (14): 2382-9
• Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour. Daw NC, Gregornik D, Rodman J, Marina N, Wu J, Kun LE, Jenkins JJ, McPherson V, Wilimas J, Jones DP. Eur J Cancer. 2009; 45 (1): 99-106
• Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children's Oncology Group. Frazier AL, Rumcheva P, Olson T, Giller R, Cushing B, Cullen J, Marina N, London WB. Pediatr Blood Cancer. 2008; 50 (4): 746-51
• Complementary and alternative therapy use in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Mertens AC, Sencer S, Myers CD, Recklitis C, Kadan-Lottick N, Whitton J, Marina N, Robison LL, Zeltzer L. Pediatr Blood Cancer. 2008; 50 (1): 90-7
• Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Meyer JS, Nadel HR, Marina N, Womer RB, Brown KL, Eary JF, Gorlick R, Grier HE, Randall RL, Lawlor ER, Lessnick SL, Schomberg PJ, Kailo MD. Pediatr Blood Cancer. 2008; 51 (2): 163-70
• Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, Bhatia S, Meeske K, Chen MH, Kinahan KE, Steinberger J, Rosenthal D. Pediatrics. 2008; 121 (2): e387-96
• Osteosarcoma: the same old drugs or more? Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS, Reaman GH. J Clin Oncol. 2008; 26 (18): 3102-3; author reply 3104-5
• Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter L, Gebhardt M, Grier HE. Pediatr Blood Cancer. 2008; 51 (3): 334-8
• Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort. Goldsby R, Burke C, Nagarajan R, Zhou T, Chen Z, Marina N, Friedman D, Neglia J, Chuba P, Bhatia S. Cancer. 2008; 113 (9): 2597-604
• Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Burke ME, Albritton K, Marina N. Cancer. 2007; 110 (11): 2385-93
• Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, Cox C, Phipps S, Pompeu R, Rosenthal D. J Clin Oncol. 2007; 25 (24): 3635-43
• Chronic health conditions in adult survivors of childhood cancer. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL. N Engl J Med. 2006; 355 (15): 1572-82
• Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. Marina N, London WB, Frazier AL, Lauer S, Rescorla F, Cushing B, Malogolowkin MH, Castleberry RP, Womer RB, Olson T. J Clin Oncol. 2006; 24 (16): 2544-8
• Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, Rescorla F, Billmire DF, Davis MM, Perlman EJ, Giller R, Lauer SJ, Olson TA. Cancer. 2005; 104 (4): 841-7
• High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission. Marina N, Meyers PA. J Clin Oncol. 2005; 23 (19): 4262-4
• Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Verneris MR, Arshi A, Edinger M, Kornacker M, Natkunam Y, Karami M, Cao YA, Marina N, Contag CH, Negrin RS. Clin Cancer Res. 2005; 11 (12): 4561-70
• Biology and therapeutic advances for pediatric osteosarcoma. Marina N, Gebhardt M, Teot L, Gorlick R. Oncologist. 2004; 9 (4): 422-41
• Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, Darling J, Armstrong FD, Blatt J, Constine LS, Freeman CR, Friedman DL, Green DM, Marina N, Meadows AT, Neglia JP, Oeffinger KC, Robison LL, Ruccione KS, Sklar CA, Hudson MM. J Clin Oncol. 2004; 22 (24): 4979-90
• Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, Rogers PC, Colombani P, Rescorla F, Billmire DF, Vinocur CD, Hawkins EP, Davis MM, Perlman EJ, London WB, Castleberry RP. J Clin Oncol. 2004; 22 (13): 2691-700
• Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. Rogers PC, Olson TA, Cullen JW, Billmire DF, Marina N, Rescorla F, Davis MM, London WB, Lauer SJ, Giller RH, Cushing B. J Clin Oncol. 2004; 22 (17): 3563-9
• Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Clin Cancer Res. 2003; 9 (15): 5442-53
• Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Hudson MM, Mertens AC, Yasui Y, Hobbie W, Chen H, Gurney JG, Yeazel M, Recklitis CJ, Marina N, Robison LR, Oeffinger KC. JAMA. 2003; 290 (12): 1583-92
• Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, Link MP. Clin Cancer Res. 2002; 8 (2): 413-8
• Recurrent mercaptopurine-induced acute pancreatitis: a rare complication of chemotherapy for acute lymphoblastic leukemia in children. Willert JR, Dahl GV, Marina NM. Med Pediatr Oncol. 2002; 38 (1): 73-4
• Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. Meyer WH, Pratt CB, Poquette CA, Rao BN, Parham DM, Marina NM, Pappo AS, Mahmoud HH, Jenkins JJ, Harper J, Neel M, Fletcher BD. J Clin Oncol. 2001; 19 (1): 171-82
• New molecular targets and biological therapies in sarcomas. Scappaticci FA, Marina N. Cancer Treat Rev. 2001; 27 (6): 317-26
• Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. Bonilla M, Moreno N, Marina N, deReyes G, Shurtleff SA, Downing JR, Behm FG, Harrison PL, Ribeiro RC, Peña O, Crist WM, Antillon FG. J Pediatr Hematol Oncol. 2000 Nov-Dec; 22 (6): 495-501
• Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. Marina NM, Poquette CA, Cain AM, Jones D, Pratt CB, Meyer WH. J Pediatr Hematol Oncol. 2000 Mar-Apr; 22 (2): 112-8
• Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. Rodriguez-Galindo C, Poquette CA, Marina NM, Head DR, Cain A, Meyer WH, Santana VM, Pappo AS. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22 (4): 321-9
• Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robison L. J Clin Endocrinol Metab. 2000; 85 (9): 3227-32
• Late effects of treatment for germ cell tumors during childhood and adolescence. Hale GA, Marina NM, Jones-Wallace D, Greenwald CA, Jenkins JJ, Rao BN, Luo X, Hudson MM. J Pediatr Hematol Oncol. 1999 Mar-Apr; 21 (2): 115-22
• Biology and therapy of pediatric malignant solid tumors. Marina N, Cancer Chemother Biol Response Modif. 1999: 18 550-89
• Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA, Pratt CB, Greenwald C, Meyer WH. J Clin Oncol. 1999; 17 (1): 180-90
• Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Marina NM, Cushing B, Giller R, Cohen L, Lauer SJ, Ablin A, Weetman R, Cullen J, Rogers P, Vinocur C, Stolar C, Rescorla F, Hawkins E, Heifetz S, Rao PV, Krailo M, Castleberry RP. J Clin Oncol. 1999; 17 (7): 2137-43
• Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group. Cushing B, Giller R, Ablin A, Cohen L, Cullen J, Hawkins E, Heifetz SA, Krailo M, Lauer SJ, Marina N, Rao PV, Rescorla F, Vinocur CD, Weetman RM, Castleberry RP. Am J Obstet Gynecol. 1999; 181 (2): 353-8
• Nongestational choriocarcinoma in the postpartum period: a case report. Suryanarayan K, O'Hanlan KA, Surti U, Ishwad CS, Nowels K, Letourneau D, Marina N. J Pediatr Hematol Oncol. 1998 Mar-Apr; 20 (2): 169-73
• Comparison of cytokines in children with recurrent solid tumors treated with intensive chemotherapy. Furman WL, Luo X, Marina N, Garrison L, Pratt CB, Meyer WH. J Pediatr Hematol Oncol. 1998 Jan-Feb; 20 (1): 62-8
• Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. Gururangan S, Marina NM, Luo X, Parham DM, Tzen CY, Greenwald CA, Rao BN, Kun LE, Meyer WH. J Pediatr Hematol Oncol. 1998 Jan-Feb; 20 (1): 55-61
• Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. Furman WL, Rodman JH, Tonda ME, Luo X, Arnold B, Marina N, Garrison L, Hanna R, Pratt CB, Meyer WH. Cancer Chemother Pharmacol. 1998; 41 (3): 229-36
• Peritoneal metastases in children with cancer. Kaste SC, Marina N, Fryrear R, Hedlund GL, Jones L, Poe D, Jenkins JJ. Cancer. 1998; 83 (2): 385-90
• Wilms' tumour. Optimal treatment strategies. Suryanarayan K, Marina N. Drugs. 1998; 56 (4): 598-605
• Biology and treatment of pediatric malignant solid tumors. Marina NM, Cancer Chemother Biol Response Modif. 1997: 17 642-71
• Is primitive neuroectodermal tumor of the kidney a distinct entity? Rodriguez-Galindo C, Marina NM, Fletcher BD, Parham DM, Bodner SM, Meyer WH. Cancer. 1997; 79 (11): 2243-50
• Long-term survivors of childhood cancer. The medical consequences of cure. Marina N, Pediatr Clin North Am. 1997; 44 (4): 1021-42
• Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors. Furman WL, Luo X, Fairclough D, Garrison L, Marina N, Pratt CB, Bleyer A, Meyer WH. Med Pediatr Oncol. 1997; 28 (6): 444-50
• Cytomegalovirus causing pericarditis with tamponade in an adolescent with cancer. Razzouk BI, Patrick CC, Marina N. Med Pediatr Oncol. 1996; 26 (1): 70
• Local control in synchronous bilateral Wilms tumor. Paulino AC, Wilimas J, Marina N, Jones D, Kumar M, Greenwald C, Chen G, Kun LE. Int J Radiat Oncol Biol Phys. 1996; 36 (3): 541-8
• Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience. Pratt CB, Luo X, Fang L, Marina N, Avery L, Furman WL. Med Pediatr Oncol. 1996; 27 (3): 145-8
• Sacrococcygeal yolk sac carcinoma: imaging findings during treatment. Kaste SC, Bridges JO, Marina NM. Pediatr Radiol. 1996; 26 (3): 212-9
• St Jude Children's Research Hospital's International Outreach Program. Ribeiro RC, Marina N, Crist WM. Leukemia. 1996; 10 (3): 570-4
• A phase I study of sulofenur in refractory pediatric malignant solid tumors. Pratt CB, Bowman LC, Marina N, Pappo A, Avery L, Luo X, Meyer WH. Invest New Drugs. 1995; 13 (1): 63-6
• Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Marina NM, Greenwald CA, Fairclough DL, Thompson EI, Wilimas JA, Mackert PW, Hudson MM, Stokes DC, Bozeman PM. Cancer. 1995; 75 (7): 1706-11
• Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Marina NM, Shema SJ, Bowman LC, Rodman J, Douglass EC, Furman WL, Pappo A, Santana VM, Hudson M, Meyer WH. Med Pediatr Oncol. 1994; 23 (4): 328-34
• Lack of heritability in ovarian germ cell malignancies. Shulman LP, Muram D, Marina N, Jones C, Portera JC, Wachtel SS, Simpson JL, Elias S. Am J Obstet Gynecol. 1994; 170 (6): 1803-5; discussion 1805-8
• Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. Marina NM, Rodman JH, Murry DJ, Shema SJ, Bowman LC, Jones DP, Furman W, Meyer WH, Pratt CB. J Natl Cancer Inst. 1994; 86 (7): 544-8
• Phase I study of topotecan for pediatric patients with malignant solid tumors. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT. J Clin Oncol. 1994; 12 (3): 539-43
• Primary malignancy of the salivary gland in children. Rogers DA, Rao BN, Bowman L, Marina N, Fleming ID, Schropp KP, Lobe TE. J Pediatr Surg. 1994; 29 (1): 44-7
• Refining therapeutic strategies for patients with resistant Wilm's tumor. Marina NM, Wilimas JA, Meyer WH, Jones DP, Douglass EC, Pratt CB. Am J Pediatr Hematol Oncol. 1994; 16 (4): 296-300
• Response of immunocompromised children with solid tumors to a conjugate vaccine for Haemophilus influenzae type b. Shenep JL, Feldman S, Gigliotti F, Roberson PK, Marina N, Foreschle JE, Fullen GH, Lott L, Brodkey TO. J Pediatr. 1994; 125 (4): 581-4
• Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis. Gururangan S, Horner M, Rodman JH, Marina NM. Med Pediatr Oncol. 1994; 22 (6): 414-6
• A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors. Pratt CB, Meyer WH, Douglass EC, Bowman L, Wilimas J, Ochs J, Marina N, Avery L, Thompson EI. Cancer. 1993; 71 (11): 3661-5
• Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. Hudson MM, Weinstein HJ, Donaldson SS, Greenwald C, Kun L, Tarbell NJ, Humphrey WA, Rupp C, Marina NM, Wilimas J. J Clin Oncol. 1993; 11 (6): 1080-4
• Brain metastases in osteosarcoma. Report of a long-term survivor and review of the St. Jude Children's Research Hospital experience. Marina NM, Pratt CB, Shema SJ, Brooks T, Rao B, Meyer WH. Cancer. 1993; 71 (11): 3656-60
• Candida tropicalis infections in children with leukemia. Flynn PM, Marina NM, Rivera GK, Hughes WT. Leuk Lymphoma. 1993; 10 (4-5): 369-76
• Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. Hudson MM, Greenwald C, Thompson E, Wilimas J, Marina N, Fairclough D, Kauffman W, Bozeman P, Mackert PW, Abromowitch M. J Clin Oncol. 1993; 11 (1): 100-8
• Nucleoside transport in normal and neoplastic cells. Belt JA, Marina NM, Phelps DA, Crawford CR. Adv Enzyme Regul. 1993: 33 235-52
• Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. Marina NM, Rodman J, Shema SJ, Bowman LC, Douglass E, Furman W, Santana VM, Hudson M, Wilimas J, Meyer W. J Clin Oncol. 1993; 11 (3): 554-60
• Progress in the treatment of adolescents with acute lymphoblastic leukemia. Rivera GK, Pui CH, Santana VM, Hancock ML, Mahmoud H, Sandlund JT, Ribeiro RC, Furman W, Marina N, Crist WM. Cancer. 1993; 71 (10 Suppl): 3400-5
• Use of HBA 71 and anti-beta 2-microglobulin to distinguish peripheral neuroepithelioma from neuroblastoma. Pappo AS, Douglass EC, Meyer WH, Marina N, Parham DM. Hum Pathol. 1993; 24 (8): 880-5
• Diagnosis and treatment of the most common solid tumors in childhood. Marina NM, Krance R, Ribeiro RC, Crist WM. Prim Care. 1992; 19 (4): 871-89
• Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, Fletcher B, Pratt CB. J Clin Oncol. 1992; 10 (11): 1737-42
• Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Marina NM, Pratt CB, Rao BN, Shema SJ, Meyer WH. Cancer. 1992; 70 (11): 2722-7
• Leukemias and lymphomas in children. Ribeiro RC, Krance R, Marina NM, Crist WM. Prim Care. 1992; 19 (4): 853-69
• Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. Marina N, Fontanesi J, Kun L, Rao B, Jenkins JJ, Thompson EI, Etcubanas E. Cancer. 1992; 70 (10): 2568-75
• Candida tropicalis and Candida albicans fungemia in children with leukemia. Marina NM, Flynn PM, Rivera GK, Hughes WT. Cancer. 1991; 68 (3): 594-9
• Effect of nucleoside transport inhibitors on thymidine salvage and the toxicity of nucleoside analogs in mouse bone marrow granulocyte-macrophage progenitor cells. Marina NM, Belt JA. Cancer Commun. 1991; 3 (12): 367-72
• Infrared, thermistor, and glass-mercury thermometry for measurement of body temperature in children with cancer. Shenep JL, Adair JR, Hughes WT, Roberson PK, Flynn PM, Brodkey TO, Fullen GH, Kennedy WT, Oakes LL, Marina NM. Clin Pediatr (Phila). 1991; 30 (4 Suppl): 36-41; discussion 49
• The role of second-look surgery in the management of advanced germ cell malignancies. Marina NM, Rao B, Etcubanas E, Jenkins JJ, Kun L, Thompson EI. Cancer. 1991; 68 (2): 309-15
• Use of MR imaging to assess results of chemotherapy for Ewing sarcoma. Lemmi MA, Fletcher BD, Marina NM, Slade W, Parham DM, Jenkins JJ, Meyer WH. AJR Am J Roentgenol. 1990; 155 (2): 343-6
• Peripheral primitive neuroectodermal tumor (peripheral neuroepithelioma) in children. A review of the St. Jude experience and controversies in diagnosis and management. Marina NM, Etcubanas E, Parham DM, Bowman LC, Green A. Cancer. 1989; 64 (9): 1952-60